Joe Y. Chang, Ritsuko Komaki, Charles Lu, Hong Y. Wen, Pamela K. Allen, Anne Tsao, Michael Gillin, Radhe Mohan and James D. Cox Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer Cancer 117
Version of Record online: 22 MAR 2011 | DOI: 10.1002/cncr.26080
Standard therapy for stage III nonsmall cell lung cancer, concurrent chemoradiation therapy with photon (x-ray–based) therapy, is associated with significant toxicity and produces suboptimal local control. The authors found that concurrent chemotherapy and high-dose proton beam therapy was less toxic than conventional photon-based treatments and produced a total local failure rate of 20.5%.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field